The obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.
The Food and Drug Administration approved Eli Lilly's tirzepatide drug for weight loss, paving the way for even wider use of the blockbuster medication.
But the FDA's new approval means adults who have obesity or are overweight with at least one weight-related condition can use the drug, which will be marketed as Zepbound, for chronic weight management.A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, on March 29, 2023.
But the FDA's new approval means adults who have obesity or are overweight with at least one weight-related condition can use the drug, which will be marketed as Zepbound, for chronic weight management. "Obesity and overweight are serious conditions that can be associated with some of the leading causes of death such as heart disease, stroke and diabetes," said Dr. John Sharretts, director of the division of diabetes, lipid disorders, and obesity in the FDA's Center for Drug Evaluation and Research. "In light of increasing rates of both obesity and overweight in the United States, today's approval addresses an unmet medical need.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and WegovyBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.The drug, which will be sold as Zepbound as an anti-obesity treatment, had previously been cleared by the FDA for the treatment of Type 2 diabetes
Read more »
FDA approves Eli Lilly's tirzepatide for obesity, paving way for even wider use of blockbuster drugThe obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.
Read more »
FDA approves Eli Lilly's tirzepatide for obesity, paving way for even wider use of blockbuster drugThe obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.
Read more »
Data on Pfizer's New Weight Loss Pill Is Coming. Why it's Crucial for the Stock.The company desperately needs some of the obesity drug fervor that's lifted Lilly and Novo.
Read more »
Data on Pfizer's New Weight Loss Pill Is Coming. Why it's Crucial for the Stock.The company desperately needs some of the obesity drug fervor that's lifted Lilly and Novo.
Read more »